- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
First-Line Bevacizumab Does Not Improve Survival in Glioblastoma
June 2nd 2013, 1:14pm
Adding bevacizumab to a standard treatment regimen for glioblastoma consisting of chemoradiation with temozolomide in newly diagnosed patients does not improve OS and did not significantly improve PFS.
Richard Gray on a Longer Duration of Tamoxifen
June 2nd 2013, 12:28pm
Richard G. Gray, MA, MSc, from the University of Oxford in Oxford, United Kingdom, discusses the phase III aTTom trial that explored a longer duration of treatment with tamoxifen in women with estrogen receptor-positive early breast cancer.
Dr. Brose on Sorafenib in RAI-Resistant Thyroid Cancer
June 2nd 2013, 10:33am
Marcia Brose, MD, PhD, from the Abramson Cancer Center at the University of Pennsylvania, discusses the phase III DECISION study that explored sorafenib in radioactive iodine-resistant differentiated thyroid cancer.
GM-CSF Boosts Ipilimumab Efficacy in Metastatic Melanoma
June 2nd 2013, 7:50am
Adding the white blood cell booster granulocyte-macrophage colony-stimulating factor to the immunotherapy ipilimumab extended survival in patients with metastatic melanoma when compared with ipilimumab alone and may be a safer alternative than monotherapy.
Dr. Heinemann Reviews the FIRE-3 Trial Results
June 2nd 2013, 7:38am
Volker Heinemann, MD, PhD, from the University of Munich, discusses results from the phase III FIRE-3 trial that looked at FOLFIRI plus bevacizumab or cetuximab as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer.
Partners of HPV-Positive Oropharyngeal Cancer Patients Not at Increased Risk of HPV Infection or Oral Cancer
June 2nd 2013, 7:31am
Patients with human papilloma virus–positive oropharyngeal cancer and their spouses may find some reassurance in a study that found that partners are no more likely to be infected by HPV than the general population.
Maintenance Therapy With Pazopanib Delays Relapse of Advanced Ovarian Cancer
June 2nd 2013, 7:03am
An oral targeted drug already approved by the FDA for the treatment of kidney cancer and soft tissue sarcoma has been found to extend disease-free survival in women with advanced ovarian cancer.
Dr. Tewari on Bevacizumab in Advanced Cervical Cancer
June 2nd 2013, 6:15am
Krishnansu S. Tewari, MD, from the University of California Irvine in Orange, California, discusses the effectiveness of bevacizumab in relapsed and metastatic cervical cancer.
Cetuximab OS Results Top Bevacizumab in mCRC
June 2nd 2013, 5:35am
Frontline cetuximab plus FOLFIRI chemotherapy improved overall survival by 3.7 months versus bevacizumab plus FOLFIRI in patients with KRAS wild-type metastatic colorectal cancer.
Nivolumab Delivers Enduring Benefits in Advanced Melanoma
June 2nd 2013, 5:26am
Nivolumab has demonstrated an overall objective response rate of 31% with a median duration of two years in patients with advanced melanoma.
Dr. Sznol Describes Nivolumab in Advanced Melanoma
June 2nd 2013, 5:23am
Mario Sznol, MD, from the Yale Cancer Center, discusses the long-term follow-up results from an expanded phase I study investigating the anti-PD-1 drug nivolumab in patients with advanced melanoma.
Dr. D'Souza on Spouses of HPV-Positive Patients
June 1st 2013, 11:41am
Gypsyamber D‘Souza, PhD, MPH, MS, from Johns Hopkins University, discusses the prevalence of oral HPV infections in the spouses of patients with HPV-positive oropharyngeal cancer.
Dr. du Bois on Pazopanib in Advanced Ovarian Cancer
June 1st 2013, 10:03am
Andreas du Bois, MD, from Kliniken Essen Mitte in Essen, Germany, discusses a phase III trial exploring the effectiveness of treatment with maintenance pazopanib for patients with advanced ovarian cancer.
Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma
June 1st 2013, 8:57am
Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition in patients with advanced uveal melanoma using the agent selumetinib.
ASCO Highlights Put Variety in Spotlight
June 1st 2013, 6:15am
New data on emerging immunotherapies and fresh findings about established agents are likely to dominate clinical and marketplace news from this year's Annual Meeting of the ASCO, according to industry analysts.
Dr. O'Shaughnessy on Everolimus in Breast Cancer
June 1st 2013, 5:22am
Joyce A. O'Shaughnessy, MD, the Co-Director of Breast Cancer Research at the Baylor Charles A. Sammons Cancer Center, describes potentially practice changing findings from the BOLERO-3 trial.
ASCO Opens 49th Annual Meeting Urging More Federal Funding for Research
June 1st 2013, 5:15am
The American Society of Clinical Oncology kicked off its 49th Annual Meeting with leaders urging all stakeholders in cancer care to vigorously oppose cuts to vital US biomedical research funding.
Dr. Pazdur on Breakthrough Designation Requirements
May 31st 2013, 1:03pm
Richard Pazdur, MD, from the FDA's Center for Drug Evaluation and Research, emphasizes the importance of adequate data supporting proposals to the FDA for breakthrough therapy designations.
Combining Ipilimumab and Nivolumab Shows Promise in Advanced Melanoma
May 16th 2013, 4:55pm
Combining the checkpoint antibodies ipilimumab and nivolumab led to deep tumor regression in approximately one-third of patients with advanced melanoma.
High Levels of Cardiovascular Fitness Reduces the Risk of Developing and Dying From Cancer
May 15th 2013, 2:07pm
Men with a high level of cardiovascular fitness at middle age had a reduced risk of developing and dying from lung and colorectal cancer later in life.